Prazosin’s Efficacy and Safety for REM‑Related Sleep Disturbances

Efficacy for Nightmare Reduction

• In patients experiencing recurrent nightmares (primarily those with PTSD), the American Academy of Sleep Medicine reports that prazosin significantly reduces nightmare frequency and intensity, based on multiple randomized controlled trials; no adverse effects on NREM sleep architecture were observed. Level of evidence: high (multiple RCTs) 1

Safety Profile Compared with Other Sedatives

• Across several clinical trials, prazosin was well tolerated, with only mild orthostatic hypotension and transient dizziness reported, contrasting with the broader adverse‑effect spectrum of alternative agents such as quetiapine. Level of evidence: moderate (multiple trial data) 2

Therapeutic Dosing and Lack of NREM Disruption

• The recommended therapeutic window for nightmare reduction is 1–16 mg taken at bedtime; within this range, prazosin does not impair NREM sleep stages, making it a safer option when REM‑related disturbances are the primary target. Level of evidence: moderate (guideline‑based recommendation) [1][2]4